KCT0000678
Recruiting
未知
Treatment Strategies and outcomes fo Acute Symptomatic internal Carotid Artery Occlusion in Korea
ConditionsDiseases of the nervous system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the nervous system
- Sponsor
- Seoul National University Bundang Hospital
- Enrollment
- 350
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Consecutive patients with ischemic symptomatic internal carotid artery occlusion within 12 hours of symptom onset
Exclusion Criteria
- •Patients without images work\-up for internal carotid artery occlusion were excluded.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Outcomes of Treatments for Acute Attack of Primary Angle Closureprimary angle closureJPRN-UMIN000042879Kitasato University109
Recruiting
Not Applicable
A study of the range of clinical menifestations and future outcome of acute noncompressive myelopathy patients.CTRI/2011/091/000003I30
Active, not recruiting
Not Applicable
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks - REAL LIFEEUCTR2005-003485-42-DEycomed GmbH2,000
Active, not recruiting
Phase 1
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeksRespuesta al tratamiento en pacientes con síntomas debidos a la enfermedad por reflujo gastroesofágico, con o sin esofagitis, tratados con 40 mg de pantoprazol sódico o.d. durante 8 semanas” - REAL LIFEEUCTR2005-003485-42-ESALTANA Pharma AG2,000
Active, not recruiting
Not Applicable
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks - REAL LIFEgastroesophageal reflux diseaseMedDRA version: 8.1Level: lltClassification code 10017885EUCTR2005-003485-42-ATALTANA Pharma AG2,000